Clinically–relevant anticancer-antidepressant drug interactions

Bibliography

• Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res 1998;8(3):215-37
   Google Scholar
• Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003;54(3):269-82
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006;28(5):396-402
   PubMed Web of Science ®Google Scholar
• Lim L. Diagnosis and management of depression in terminal cancer. SGH Proc 2007;16(2):88-96
   Google Scholar
• Gross AF, Smith FA, Stern TA. Is depression an appropriate response to having cancer? A discussion of diagnostic criteria and treatment decisions. Prim Care Companion J Clin Psychiatry 2007;9(5):382-7
   PubMedGoogle Scholar
• Grassi L, Rosti G. Psychosocial morbidity and adjustment to illness among long-term cancer survivors. A six-year follow-up study. Psychosomatics 1996;37(6):523-32
   PubMed Web of Science ®Google Scholar
• Spiegel D, Kato PM. Psychosocial influences on cancer incidence and progression. Harv Rev Psychiatry 1996;4(1):10-26
   PubMed Web of Science ®Google Scholar
• Polsky D, Doshi JA, Marcus S, Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005;165(11):1260-6
   PubMed Web of Science ®Google Scholar
• Yap KY, Tay WL, Chui WK, Chan A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl) 2011;20(1):6-32
   PubMed Web of Science ®Google Scholar
• Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005;55(2):117-42
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y, Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry 2001;62(Suppl 8):64-7
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol 2004;5(8):489-96
   PubMed Web of Science ®Google Scholar
• McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998;45(6):539-44
   PubMed Web of Science ®Google Scholar
• Tatro DS. Drug Interaction Facts: The Authority on Drug Interactions. 2008th edition. Facts & Comparisons; St. Louis, MO: 2008
   Google Scholar
• Preskorn S, Werder S. Detrimental antidepressant drug-drug interactions: are they clinically relevant? Neuropsychopharmacology 2006;31(8):1605-12
   PubMed Web of Science ®Google Scholar
• Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30(7):1206-27
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. AHFS Drug Information. 2007th edition. American Society of Health-System Pharmacists, Inc; Bethesda, MD: 2007
   Google Scholar
• British Medical Association, Pharmaceutical Society of Great Britain. British National Formulary. 53rd edition. BMJ Publishing Group Ltd & RPS Publishing; London, UK: 2007
   Google Scholar
• Hansten PD, Horn JR. Hansten and Horn's Drug Interactions Analysis and Management. 3rd edition. Lippincott Williams & Wilkins; Vancouver, WA: 2008
   Google Scholar
• Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook with International Trade Names Index. 15th edition. Lexi-comp, Inc.; Hudson, OH: 2007.
   Google Scholar
• Solimando DAJ. Drug Information Handbook for Oncology. 6th edition. Lexi-comp; Hudson, OH: 2007
   Google Scholar
• BC Cancer Agency. BCCA cancer drug manual. Available from: http://www.bccancer.bc.ca/HPI/DrugDatabase/default.htm [Last accessed 1 August 2011]
   Google Scholar
• Wishart DS, Knox C, Guo AC, DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue):D668-D72
   Google Scholar
• Klein TE, Chang JT, Cho MK, Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J 2001;1(3):167-70
   PubMedGoogle Scholar
• Thomson Healthcare. Thomson Reuters Healthcare. Micromedex® Thomson Reuters Healthcare Series (version 5.1) [intranet database]. Available from: http://www.thomsonhc.com/hcs/librarian/PFPUI/fV1mNyY303TXxR [Last accessed 1 August 2011]
   Google Scholar
• UpToDate, Inc. UpToDate Online 16.2 [Intranet Database]. Available from: http://www.uptodateonline.com [Last accessed 1 August 2011]
   Google Scholar
• Everyday Health, Inc. Drugs A-Z on Everyday Health. Available from: http://drugchecker.aolhealth.com/ [Last accessed 1 August 2011]
   Google Scholar
• Gold Standard, Inc. Caremark Drug Interactions. Available from: http://cpref.goldstandard.com/inter.asp?r=8084 [Last accessed 1 August 2011]
   Google Scholar
• Discovery Communications LLC. Discovery Health Drug Interaction Checker. Available from: http://health.discovery.com/webapps/drugchecker.do%3FjspLetter=A [Last accessed 1 August 2011]
   Google Scholar
• Enhanced Medical Decisions, Inc. DoublecheckMD.com™. Available from: http://www.doublecheckmd.com [Last accessed 1 August 2011]
   Google Scholar
• Drugsite Trust. Drugs.com™: drug interactions checker. Available from: http://www.drugs.com/drug_interactions.html [Last accessed 1 August 2011]
   Google Scholar
• Express Scripts, Inc. Drug Digest. Available from: http://www.drugdigest.org/wps/portal/ddigest [Last accessed 1 August 2011]
   Google Scholar
• Thomson Reuters. Physicians' Desktop Reference (PDRhealth™). Available from: http://www.pdrhealth.com/ [Last accessed 1 August 2011]
   Google Scholar
• WebMD LLC. Medscape® drug interaction checker. Available from: http://www.medscape.com/druginfo/druginterchecker [Last accessed 1 August 2011]
   Google Scholar
• Stockley IH. Drug interactions. 5th edition. Pharmaceutical Press; London: 1999
   Google Scholar
• Chan A, Yap KY, Koh D, Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. Pharmacoepidemiol Drug Saf 2011; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Wickerham DL, Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15(5):1858-69
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown AM, Dimitrov NV, Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8(9):1483-96
   PubMed Web of Science ®Google Scholar
• Smalley RV, Lefante J, Bartolucci A, A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 1983;3(2):209-20
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Evans WK, Shepherd FA, Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997;15(5):1897-905
   PubMed Web of Science ®Google Scholar
• French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000;18(17):3115-24
   PubMed Web of Science ®Google Scholar
• Levine MN, Bramwell VH, Pritchard KI, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16(8):2651-8
   PubMed Web of Science ®Google Scholar
• Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23(7):881-908
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56(1):1-18
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Vaccheri A, Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002;54(2):171-7
   PubMed Web of Science ®Google Scholar
• Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 2000;83(1):1-19
   PubMedGoogle Scholar
• Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110(5):385-98
   PubMed Web of Science ®Google Scholar
• Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003;23(1):58-77
   PubMed Web of Science ®Google Scholar
• Damkier P, Hansen LL, Brøsen K. Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999;55(6):451-6
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46(1):35-9
   PubMed Web of Science ®Google Scholar
• Sandoz, Inc. Fluvoxamine maleate tablet [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Princeton, NJ: 2007
   Google Scholar
• Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ 2000;320(7243):1158-9
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005;77(6):553-9
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline, Inc. Zyban® (bupropion hydrochloride) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Research Triangle Park, NC: 2007
   Google Scholar
• Richter T, Murdter TE, Heinkele G, Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004;308(1):189-97
   PubMed Web of Science ®Google Scholar
• Kashuba ADM, Nafziger AN, Kearns GL, Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64(3):257-68
   PubMed Web of Science ®Google Scholar
• Baumhakel M, Kasel D, Rao-Schymanski RA, Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001;39(12):517-28
   PubMed Web of Science ®Google Scholar
• Kerbusch T, Jansen RL, Mathot RA, Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 2001;70(2):132-41
   PubMed Web of Science ®Google Scholar
• van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;11(3):77-98
   PubMed Web of Science ®Google Scholar
• Paiva CE, Paiva BS, Michelin OC. Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy? Sao Paulo Med J 2009;127(6):385-6
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema AD, Holtkamp MJ, Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56(4):370-8
   PubMed Web of Science ®Google Scholar
• Colleoni M, Gelber S, Goldhirsch A, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24(9):1332-41
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80(1):61-74
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97(1):30-9
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95(23):1758-64
   PubMed Web of Science ®Google Scholar
• Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995;10(Suppl 1):15-21
   PubMedGoogle Scholar
• Lehmann D, Nelsen J, Ramanath V, Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 2004;44(8):861-5
   PubMed Web of Science ®Google Scholar
• Reese MJ, Wurm RM, Muir KT, An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008;36(7):1198-201
   PubMed Web of Science ®Google Scholar
• Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion. Ther Drug Monit 2002;24(3):436-7
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97(1):30-9
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101(1):113-21
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Nolvadex® (tamoxifen citrate) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Wilmington, DE: 2003
   Google Scholar
• Kelly CM, Juurlink DN, Gomes T, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. 2010;340:c693
   Google Scholar
• Dezentje VO, van Blijderveen NJ, Gelderblom H, Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010;28(14):2423-9
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343(13):905-14
   PubMed Web of Science ®Google Scholar
• Rivory LP. Metabolism of CPT-11: impact on activity. Ann NY Acad Sci 2000;922:205-15
   PubMed Web of Science ®Google Scholar
• Hanioka N, Ozawa S, Jinno H, Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 2002;30(4):391-6
   PubMed Web of Science ®Google Scholar
• Richards S, Umbreit JN, Fanucchi MP, Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. South Med J 2003;96(10):1031-3
   PubMed Web of Science ®Google Scholar
• Forest Pharmaceuticals, Inc. Lexapro® (escitalopram oxalate) tablets and solution [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); St. Louis, MO: 2007
   Google Scholar
• Mathijssen RHJ, Verweij J, Bruijn PD, Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94(16):1247-9
   PubMed Web of Science ®Google Scholar
• Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions. Curr Drug Metab 2008;9(10):1027-37
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisgand D, Douillard JY, Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12(2):360-7
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE II, Maddaus MA, Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26(31):5043-51
   PubMed Web of Science ®Google Scholar
• Aventis Pharmaceuticals, Inc. Taxotere® (docetaxel) injection concentrate [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Bridgewater, NJ: 2003
   Google Scholar
• Marre F, Sanderink GJ, de Sousa G, Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56(6):1296-302
   PubMed Web of Science ®Google Scholar
• Cresteil T, Monsarrat B, Alvinerie P, Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54(2):386-92
   PubMed Web of Science ®Google Scholar
• Abraxis Oncology. Abraxane® (paclitaxel protein-bound particles) for injectable suspension [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Los Angeles, CA: 2007
   Google Scholar
• Bristol-Myers Squibb Oncology. Taxol® (paclitaxel) injection [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Princeton, NJ: 2003
   Google Scholar
• van Schaik RHN. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005;23(6):513-22
   PubMed Web of Science ®Google Scholar
• Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe vincristine neurotoxicity with concomitant use of itraconazole. J Paediatr Child Health 2003;39(8):638-9
   PubMed Web of Science ®Google Scholar
• Bermudez M, Fuster JL, Llinares E, Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005;27(7):389-92
   PubMed Web of Science ®Google Scholar
• Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998;18(6):1304-7
   PubMed Web of Science ®Google Scholar
• Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998;20(2):123-4
   PubMedGoogle Scholar
• Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001;18(2):137-42
   PubMed Web of Science ®Google Scholar
• Kamaluddin M, McNally P, Breatnach F, Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90(10):1204-7
   PubMed Web of Science ®Google Scholar
• Sathiapalan RK, Al-Nasser A, El-Solh H, Vincristine-itraconazole interaction: cause for increasing concern. J Pediatr Hematol Oncol 2002;24(7):591
   PubMed Web of Science ®Google Scholar
• Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 2001;18(8):543-6
   PubMed Web of Science ®Google Scholar
• Takahashi N, Kameoka Y, Yamanaka Y, Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Intern Med 2008;47(7):651-3
   PubMed Web of Science ®Google Scholar
• Tobe SW, Siu LL, Jamal SA, Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995;35(3):188-90
   PubMed Web of Science ®Google Scholar
• Zhou-Pan XR, Seree E, Zhou XJ, Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53(21):5121-6
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3(1):13-37
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Lindeman NI, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25(7):760-6
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47
   PubMed Web of Science ®Google Scholar
• Dongiovanni D, Daniele L, Barone C, Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer 2008;61(1):73-81
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T, Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26(26):4244-52
   PubMed Web of Science ®Google Scholar
• OSI Pharmaceuticals, Inc., Genentech, Inc. Tarceva® (erlotinib) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Melville, NY and South San Francisco, CA: 2004
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Iressa® (gefitinib) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Wilmington, DE: 2005
   Google Scholar
• Swaisland HC, Ranson M, Smith RP, Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44(10):1067-81
   PubMed Web of Science ®Google Scholar
• Wilson WH, Bryant G, Bates S, EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11(8):1573-82
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16(12):3803-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O'Brien S, Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101(12):2788-801
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346(4):235-42
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22(23):4711-16
   PubMed Web of Science ®Google Scholar
• Devita VTJ, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73(6):881-95
   PubMed Web of Science ®Google Scholar
• Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990;17(6):716-35
   PubMed Web of Science ®Google Scholar
• Engert A, Franklin J, Eich HT, Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25(23):3495-502
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148(6):705-13
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342(8884):1419
   PubMed Web of Science ®Google Scholar
• Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993;150(5):837
   PubMed Web of Science ®Google Scholar
• Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51(6):222-5
   PubMed Web of Science ®Google Scholar
• Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994;28(6):732-5
   PubMed Web of Science ®Google Scholar
• Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 1997;16(1):14-17
   PubMed Web of Science ®Google Scholar
• Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 2006;26(2):269-76
   PubMed Web of Science ®Google Scholar
• Sjoqvist F. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med 1965;58(11 Part 2):967-78
   PubMedGoogle Scholar
• Spiker DG, Pugh DD. Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch Gen Psychiatry 1976;33(7):828-30
   PubMed Web of Science ®Google Scholar
• Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 1971;24(6):509-14
   PubMed Web of Science ®Google Scholar
• White K, Simpson G. The combined use of MAOIs and tricyclics. J Clin Psychiatry 1984;45(7 Pt 2):67-9
   PubMed Web of Science ®Google Scholar
• Drugsite Trust. Drugs.com™: drug information online. Available from: http://www.drugs.com [Last accessed 1 August 2011]
   Google Scholar
• Massoud M, Armand JP, Ribrag V. Procarbazine in haematology: an old drug with a new life? Eur J Cancer 2004;40(13):1924-7
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. Prozac® (fluoxetine hydrochloride) capsules [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Indianapolis, IN: 2008
   Google Scholar
• Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994;331(15):1021-2
   PubMed Web of Science ®Google Scholar
• Sweetman SC. Martindale: the complete drug reference. 33rd edition. Pharmaceutical Press; London, UK: 2002
   Google Scholar
• Organon USA, Inc. Remeron® (mirtazapine) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Roseland, NJ: 2007
   Google Scholar
• Merck & Co., Inc. Decadron® (dexamethasone tablets USP) [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Whitehouse Station, NJ: 2004
   Google Scholar
• Pichard L, Fabre I, Daujat M, Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41(6):1047-55
   PubMed Web of Science ®Google Scholar
• Pharmacia and Upjohn Co. Deltasone® (prednisone) tablet USP [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); New York, NY: 2006
   Google Scholar
• Bayer HealthCare Pharmaceuticals, Inc. Nexavar® (sorafenib) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Wayne, NJ: 2008
   Google Scholar
• Wyeth Pharmaceuticals, Inc. Torisel® kit (temsirolimus) injection [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Philadelphia, PA: 2008
   Google Scholar
• Novartis Pharmaceuticals Corp. Gleevec™ (imatinib mesylate) capsules [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); East Hanover, NJ: 2001 & 2005
   Google Scholar
• Belle DJ, Ernest CS, Sauer J-M, Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002;42(11):1219-27
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44(9):879-94
   PubMed Web of Science ®Google Scholar
• Roerig. Zoloft® (sertraline hydrochloride) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); New York, NY: 2008
   Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, Effect of St John's Wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76(4):323-9
   PubMed Web of Science ®Google Scholar
• Smith P, Bullock JM, Booker BM, The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24(11):1508-14
   PubMed Web of Science ®Google Scholar
• Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57(5):365-76
   PubMed Web of Science ®Google Scholar
• Celgene Corp. Thalomid® (thalidomide) capsules [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Summit, NJ: 2003
   Google Scholar
• Kuhn WL, Van Maanen EF. Central nervous system effects of thalidomide. J Pharmacol Exp Ther 1961;134:60-8
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Di YM, Chan E, Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9(8):738-84
   PubMed Web of Science ®Google Scholar
• Shai RM, Reichardt JKV, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008;4(4):525-34
   PubMed Web of Science ®Google Scholar
• Yap KY, Chan A, Chui WK. Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. Lancet Oncol 2009;10(10):1011-19
   PubMed Web of Science ®Google Scholar
• Hernandez-Boussard T, Whirl-Carrillo M, Hebert JM, The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res 2008;36(Database issue):D913-D18
   PubMedGoogle Scholar
• Wishart DS, Knox C, Guo AC, DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue):D901-D06
   PubMed Web of Science ®Google Scholar
• Maruyama Y, Wakamatsu A, Kawamura Y, Human Gene and Protein Database (HGPD): a novel database presenting a large quantity of experiment-based results in human proteomics. Nucleic Acids Res 2009;37(Database issue):D762-D66
   PubMedGoogle Scholar
• He M, Wang Y, Li W. PPI finder: a mining tool for human protein-protein interactions. PLoS One 2009;4(2):e4554
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009;37(Database issue):D603-D10
   PubMed Web of Science ®Google Scholar
• Ortutay C, Vihinen M. Immunome Knowledge Base (IKB): an integrated service for immunome research. BMC Immunol 2009;10:3
   PubMedGoogle Scholar
• Smithburger PL, Buckley MS, Bejian S, A critical evaluation of clinical decision support for the detection of drug-drug interactions. Expert Opin Drug Saf 2011; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Chan A, Tan SH, Wong CM, Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009;31(Pt 2):2379-86
   PubMedGoogle Scholar
• Yap KY, Ho YX, Chui WK, Chan A. Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol 2010;49(8):1235-45
   PubMed Web of Science ®Google Scholar
• Quan D. Improving life sciences information retrieval using semantic web technology. Brief Bioinform 2007;8(3):172-82
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research Human Epigenome Task Force & European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature 2008;454(7205):711-15
   PubMedGoogle Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116(3):496-526
   PubMed Web of Science ®Google Scholar
• Szyf M. Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2004;2(4):357-77
   Google Scholar
• Peedicayil J. Epigenetic therapy - a new development in pharmacology. Indian J Med Res 2006;123(1):17-24
   PubMed Web of Science ®Google Scholar
• Krishnan KR, France RD, Ellinwood EH Jr. Tricyclic-induced akathisia in patients taking conjugated estrogens. Am J Psychiatry 1984;141(5):696-7
   PubMed Web of Science ®Google Scholar
• Vandel P, Bonin B, Leveque E, Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997;7(3):207-12
   PubMed Web of Science ®Google Scholar
• Edelbroek PM, Zitman FG, Knoppert-van der Klein EAM, Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin Chim Acta 1987;165(2-3):177-87
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984;35(6):792-7
   PubMed Web of Science ®Google Scholar
• Khurana RC. Estrogen-imipramine interaction. JAMA 1972;222(6):702-3
   PubMed Web of Science ®Google Scholar
• Somani SM, Khurana RC. Mechanism of estrogen-imipramine interaction. JAMA 1973;223(5):560
   PubMed Web of Science ®Google Scholar
• Ito D, Amano T, Sato H, Fukuuchi Y. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. J Neurol 2001;248(6):533-4
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Steward JW, Quitkin FM. A possible L-deprenyl induced hypertensive reaction. J Clin Psychopharmacol 1989;9(4):310-11
   PubMed Web of Science ®Google Scholar
• Somerset Pharmaceuticals, Inc. Emsam® (selegiline) patch [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Tampa, FL: 2006
   Google Scholar
• Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol (Oxf) 1995;42(1):95-8
   PubMed Web of Science ®Google Scholar
• Schulz R, Antonin K-H, Hoffmann E, Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989;46(5):528-36
   PubMed Web of Science ®Google Scholar
• Grimsley SR, Jann MW, Carter JG, Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50(1):10-15
   PubMed Web of Science ®Google Scholar
• DeVane CL, Donovan JL, Liston HL, Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol 2004;24(1):4-10
   PubMed Web of Science ®Google Scholar
• Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997;62(6):643-51
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Preskorn SH, Cotreau MM, Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52(5):479-86
   PubMed Web of Science ®Google Scholar
• Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9(4):310-22
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48(5):794-847
   PubMed Web of Science ®Google Scholar
• Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 1994;268(3):1160-5
   PubMed Web of Science ®Google Scholar
• Desai PB, Duan JZ, Zhu YW, Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998;23(3):417-24
   PubMed Web of Science ®Google Scholar
• Sicor Pharmaceuticals, Inc. Vincasar PFS® (vincristine sulfate injection USP) [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Irvine, CA: 2003
   Google Scholar
• Bedford Laboratories. Vinblastine sulfate for injection USP [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Bedford, OH: 2001
   Google Scholar
• Mayne Pharma (USA), Inc. Vinorelbine tartrate injection solution [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Paramus, NJ: 2004
   Google Scholar
• GTx, Inc. Fareston® (toremifene citrate) tablets [product information]. US Food and Drug Administration (FDA) and National Library of Medicine (NLM); Memphis, TN: 2004
   Google Scholar